# A Single Dose Study of LY3023703 in Healthy Participants

> **NCT01632579** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 30 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** LY3023703
- **DRUG:** Placebo
- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT01632579
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01632579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01632579, "A Single Dose Study of LY3023703 in Healthy Participants". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01632579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*